Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 6/20 | 0.44 |
| ▸ | TNKS | O95271 | 3/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | GPR4 | P46093 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22266116 | 0.88 | PARP1 (0.44) | DPP4PARP1TNKSTNKS2JAK2 | |
| SCHEMBL5672765 | 0.86 | KDM1A (0.48) | JAK2JAK1TACR1GPR119GPR4 | |
| SCHEMBL5238677 | 0.85 | ALDH1A1 (0.49) | — | |
| SCHEMBL8111848 | 0.85 | GPR119 (0.52) | TACR1GPR119 | |
| SCHEMBL22719136 | 0.84 | JAK2 (0.47) | DPP4PARP1TNKSTNKS2JAK2 | |
| SCHEMBL22265768 | 0.84 | TACR1 (0.43) | DPP4JAK2JAK1TACR1GPR119 | |
| SCHEMBL24485250 | 0.84 | MEN1 (0.53) | — | |
| SCHEMBL30027230 | 0.83 | KDM1A (0.50) | TACR1GPR4 | |
| SCHEMBL15536173 | 0.83 | KDM1A (0.50) | TACR1GPR4 | |
| SCHEMBL22266103 | 0.83 | DPP4 (0.41) | DPP4PARP1TNKSTNKS2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12268687-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-08 | — | — | US | disclosed |
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-20250034125-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-12098146-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-24 | — | — | US | disclosed |
| US-20230116101-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| CN-113906019-A | Compound and use thereof | 优曼尼蒂治疗公司 | 2022-01-07 | — | — | CN | disclosed |
| EP-3914593-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| US-11174272-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20210206781-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2021-07-08 | — | — | US | disclosed |
| WO-2021097240-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-8871766-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-8865717-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-21 | — | — | US | disclosed |
| US-20140228373-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| EP-2763979-A1 | 1 - ARYLCARBONYL - 4 - OXY - PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Takeda Pharmaceutical Company Limited (JP) | 2014-08-13 | — | — | EP | disclosed |
| CN-103842356-A | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | TAKAEDA CHEMICAL IND LTD | 2014-06-04 | — | — | CN | disclosed |
| US-20140088118-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-27 | — | — | US | disclosed |
| US-20140088146-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-27 | — | — | US | disclosed |
| US-8648079-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-02-11 | — | — | US | disclosed |
| WO-2013054822-A1 | 1 - ARYLCARBONYL - 4 - OXY - PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-18 | — | — | WO | disclosed |
| US-20130090341-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | DPP4 2008/4885PARP1 490/4885TNKS 2067/4885 |
| US-12268687-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | DPP4 2008/4885PARP1 490/4885TNKS 2067/4885 |
| US-11174272-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | DPP4 827/4885PARP1 2593/4885TNKS 3236/4885 |
| US-20140228373-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PSEN1, HTT | DPP4 885/4885PARP1 2646/4885TNKS 3580/4885 |
| US-20140088118-A1 | HETEROCYCLIC COMPOUNDS | HTT, NQO1, BDNF | DPP4 1218/4885PARP1 3233/4885TNKS 4422/4885 |
| US-20230116101-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | DPP4 2008/4885PARP1 490/4885TNKS 2067/4885 |
| US-20130090341-A1 | HETEROCYCLIC COMPOUNDS | HTT, NQO1, BDNF | DPP4 1218/4885PARP1 3233/4885TNKS 4422/4885 |
| US-20250034125-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | DPP4 2008/4885PARP1 490/4885TNKS 2067/4885 |
| US-20140088146-A1 | HETEROCYCLIC COMPOUNDS | HTT, NQO1, BDNF | DPP4 1218/4885PARP1 3233/4885TNKS 4422/4885 |
| US-12098146-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | DPP4 2008/4885PARP1 490/4885TNKS 2067/4885 |
| US-20210206781-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | DPP4 827/4885PARP1 2593/4885TNKS 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.